GCGianluca Corazzolla

Gianluca Corazzolla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gianluca Corazzolla has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lifespan Modeling of Choroid Plexus Volume in Multiple Sclerosis and Its Dynamic Associations With Clinical, MRI, and HLA Susceptibility

    by Paolo Preziosa, Gianluca Corazzolla, Alessandro Meani, Monica Margoni, Loredana Storelli, Elisabetta Pagani, Martina Rubin, Ferdinando Clarelli, Elisabetta Mascia, Melissa Sorosina, et al.

    The choroid plexus (ChP) regulates CSF production and CNS homeostasis. In multiple sclerosis (MS), ChP enlargement occurs early in the disease course, yet its normative lifespan trajectory and relationship with MS-specific features remain poorly defined. We aimed to define the normative ChP volume model, to characterize its trajectory across the healthy lifespan, and to assess ChP enlargement in MS using z-scores, evaluating associations with demographic, clinical, MRI, and genetic variables, including human leukocyte antigen (HLA) and non-HLA polygenic risk scores (PRSs). This monocentric retrospective cross-sectional study included 461 healthy controls (HCs) and 727 patients with MS (age 18–70 years) who underwent 3T brain MRI and neurologic assessment. ChP volumes were quantified using ASCHOPLEX, normalized for head size, and modeled in HCs. We derived age-related normalized ChP volume (NChPV) trajectory across adulthood. Z-scores for patients with MS were computed. PRSs were calculated from established MS susceptibility loci, encompassing both HLA and non-HLA regions. In HCs, normalized brain volume, lateral ventricle volume, and its squared term were independently associated with NChPV (R2 = 0.54). Model-derived NChPV trajectory remained stable until age 35 and then increased nonlinearly (p-FDR−2, p = 0.957). In cross-sectional analyses, NChPV z-scores, already elevated 1 year after disease onset (EM z-scores = 0.252, p-FDR−2, p < 0.001) and HLA genetic burden (standardized β = 0.097, p = 0.038), but not non-HLA PRSs (p ≥ 0.177). We provided a normative ChP volume model, characterized its trajectory across the healthy lifespan, and showed early, consistently higher ChP volume in patients with MS across ages and disease durations in cross-sectional analyses, linked to inflammatory lesion burden and HLA-mediated genetic risk. The ChP may represent a noninvasive biomarker of neuroinflammation and HLA-related immunogenetic background in MS.

  • Evidence of skull bone translocator protein overexpression linked to multiple sclerosis progression

    by Gianluca Corazzolla, Constantina A Treaba, Mehrbod Mohammadian, Ludovica Brusaferri, Valeria T Barletta, Nicole R Zürcher, Jacob M Hooker, Jacob A Sloane, Eric C Klawiter, Roberto Bomprezzi, et al.

    The skull bone marrow contributes to brain immune homeostasis via recently discovered skull-meningeal channels, enabling the bidirectional trafficking of immune cells between skull bone and underlying dura mater. In multiple sclerosis, autoreactive T cells migrate to the bone marrow and shift its hematopoietic output toward myeloid differentiation, contributing to disease progression. However, the role of the skull bone marrow in multiple sclerosis pathophysiology, and its relationship to brain damage and clinical disability remain largely unexplored. We utilized simultaneous MR-PET with the second-generation radioligand ¹¹C-PBR28 to characterize within the skull bone of multiple sclerosis patients the in vivo expression of the translocator protein (TSPO), an 18-kilodalton mitochondrial membrane protein largely expressed by microglia, astrocytes, and peripheral myeloid cells. Sixty-five multiple sclerosis subjects (46 relapsing-remitting, 19 secondary progressive) and 26 healthy controls underwent ¹¹C-PBR28 MR-PET to acquire 60–90-minute post-injection standardized uptake value maps and anatomical scans for brain volumetrics. Voxel-wise analyses of skull TSPO signal were conducted to assess group differences and associations with demographic, clinical, and brain volumetrics. Voxel-wise analyses revealed a divergent association between age and skull TSPO signal, with a negative correlation in healthy controls in bilateral frontal and right parietal regions (r=-0.67, pr=0.44, pρ=0.49, pr=-0.45, pr=-0.48, p0.550). We provide in vivo evidence of skull TSPO overexpression in multiple sclerosis, observed in progressive disease and associated with clinical disability and structural brain damage. Overall, these findings suggest a role for the skull bone marrow in disease-related processes and highlight its potential as a novel radiological marker and therapeutic target.